Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.

Journal of cancer research and therapeutics - 1 Jan 2000

Boruah Monikongkona, Gaddam Pranitha, Agarwal Shipra, Mir Riyaz Ahmad, Gupta Ranjan, Sharma Mehar C, S Deo Suryanarayana V, Nilima Nilima

Abstract excerpt

Background and Aim: Programmed cell death ligand-1 (PD-L1) immunoexpression status determines the response to immunotherapy in many cancers. Limited data exist on PD-L1 status in aggressive thyroid tumors. We investigated PD-L1 expression across thyroid cancers and correlated it with their molecular profile. Materials and Methods: Sixty-five cases of differentiated thyroid carcinoma, poorly differentiated thyroid...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma, Follicular
Share to B7-H1 Antigen

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Pilot Projects

Share to Proto-Oncogene Proteins B-raf

Share to Thyroid Cancer, Papillary

Share to Thyroid Carcinoma, Anaplastic

Share to Thyroid Neoplasms

Source

Identifiers

PMID: 37006068
DOI: 10.4103/jcrt.jcrt_1471_22

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PD-L1 expression in rare and aggressive thyroid cancers: A preliminary investigation for a role of immunotherapy.PMID 37006068Read ↗

PD-L1 Expression and Its Modulating Factors in Anaplastic Thyroid Carcinoma: A Multi-institutional Study.Semantic proximity Read ↗

PD-L1 and PD-1 expression are correlated with distinctive clinicopathological features in papillary thyroid carcinoma.Semantic proximity Read ↗

Prognostic Characterization of Papillary Thyroid Carcinoma: Insights into the Role of PD-L1 and Mutational Landscape in Disease Aggressiveness and OutcomeSemantic proximity Read ↗

Transcriptomic signatures associated with autoimmune thyroiditis in papillary thyroid carcinoma and cancer immunotherapy-induced thyroid dysfunctionSemantic proximity Read ↗

PD-L1 expression, BRAF and TERT mutation in a cohort of aggressive thyroid cancers: case series from a single-centre experience.Semantic proximity Read ↗

Prognostic characterization of papillary thyroid carcinoma: Insights into the role of PD-L1 and mutational landscape in disease aggressiveness and outcome.Semantic proximity Read ↗

The Oncocytic Variant of Poorly Differentiated Thyroid Carcinoma Shows a Specific Immune-Related Gene Expression ProfileSemantic proximity Read ↗

CTLA-4 and PD-1 Ligand Gene Expression in Epithelial Thyroid CancersSemantic proximity Read ↗

Molecular features of aggressive thyroid cancerSemantic proximity Read ↗

PD-1 Blockade Delays Tumor Growth by Inhibiting an Intrinsic SHP2/Ras/MAPK Signalling in Thyroid Cancer CellsSemantic proximity Read ↗

T cell exhaustion is associated with the risk of papillary thyroid carcinoma and can be a predictive and sensitive biomarker for diagnosis.Semantic proximity Read ↗

Novel targeted therapies and immunotherapy for advanced thyroid cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.